Galcanezumab (Emgality) prior authorization at Premera Blue Cross
Submission criteria, P2P prep, and appeal path if denied — for prescribers and PA staff
Premera Blue Cross requires prior-authorization documentation for Galcanezumab (Emgality): a diagnosis with ICD-10 code, documented step-therapy history, and prescriber attestation of medical necessity. Standard PA decisions return on the clock printed in the current member-specific payer source; if denied, use the appeal window printed on the denial notice to appeal.
The PA criteria you'll need to meet
Premera Blue Cross reviews Galcanezumab (Emgality) prior authorizations against its medical policy . Premera Blue Cross-specific context: BCBS licensee for Washington and Alaska (~2.4M members). Express Scripts PBM. WA OIC oversight. WA has strong mental health parity enforcement and surprise-billing protections that pre-date federal NSA.
Documentation packet checklist
- Chart note with diagnosis (ICD-10 code) and clinical severity markers
- Documented failure of, contraindication to, or intolerance of step-therapy alternatives in this class
- Prior treatment history including dosing, duration, and reason for discontinuation
- Relevant labs, imaging, or assessment scores supporting medical necessity
- Prescriber attestation linking the FDA-approved indication to the patient's presentation
- Premera Blue Cross's medical policy URL referenced in the cover letter
Denial scenarios to check against the current policy
These are preparation scenarios, not frequency claims. Use only those supported by the current member-specific source:
- WA-specific mental health parity violations
- Step therapy via Express Scripts
- Out-of-network reductions
- Specialty drug prior auth
Galcanezumab (Emgality)-specific review scenarios and context
Check whether the current notice cites any of these label-, REMS-, or policy-related scenarios:
- Step therapy requiring 2+ older oral preventives (topiramate, propranolol, amitriptyline)
- Migraine days threshold (≥4 monthly for episodic, ≥15 for chronic)
- Indication restriction (episodic vs chronic vs cluster)
Brand: Emgality. CGRP ligand monoclonal antibody. FDA-approved for migraine prevention (episodic and chronic) and episodic cluster headache.
Manufacturer patient-assistance program: Lilly Cares Foundation — relevant when a Premera Blue Cross denial sticks and the patient needs bridge access while appealing.
How Premera Blue Cross approaches Biologic drugs (mAbs and biosimilars) PAs
For Galcanezumab, check whether the current Premera Blue Cross Biologic drugs (mAbs and biosimilars) policy cites step therapy via express scripts or specialty drug prior auth. Pharmacy-benefit review for Galcanezumab at Premera Blue Cross is routed through Express Scripts. The applicable review clock depends on the member's current product, whether the request is complete and urgent, and governing plan rules. Confirm receipt and timing with Premera Blue Cross; if denied, use the filing date and route printed on that denial notice. Premera Blue Cross's utilization-management vendor (Carelon, eviCore, OptumRx, or in-house) sets the step-therapy ladder — appeals that cite ACR, AAD, or AGA guideline language directly to the medical director shorten escalation. Premera Blue Cross is domiciled in WA, so unresolved appeals escalate to the WA insurance department's external-review program for fully-insured policies (self-funded ERISA plans route to the DOL EBSA instead).
If the PA is denied
Verify the appeal window and decision clock in the current denial notice and member-specific payer source before relying on either. Submit through the provider portal (https://www.premera.com/wa/provider) with the same packet plus an applicable, current clinical source supporting Galcanezumab (Emgality)for the patient's indication.
Helping a patient appeal the denial directly? See the consumer guide: How to appeal a Premera Blue Cross denial on DenialHelp.
Contact Premera Blue Cross
- Provider portal: https://www.premera.com/wa/provider
Frequently asked questions
What documentation does Premera Blue Cross need for Galcanezumab (Emgality) prior auth?
Premera Blue Cross's typical PA packet for Galcanezumab (Emgality): (1) chart note documenting the indication and prior-treatment failures, (2) supporting lab/imaging where indicated, (3) prescriber attestation that step-therapy alternatives were tried or contraindicated, (4) FDA-approved indication mapped to ICD-10 diagnosis.
What's the turnaround time at Premera Blue Cross?
Verify the decision clock in the current member-specific payer policy and request receipt. Product type, urgency, state law, and plan terms can change the applicable timing; this page does not supply an operational deadline.
What documentation issues should be checked for Galcanezumab (Emgality) at Premera Blue Cross?
Preparation scenarios to check against the current notice and policy include: WA-specific mental health parity violations; Step therapy via Express Scripts; Out-of-network reductions. These are not measured frequency claims. For Galcanezumab (Emgality), verify whether the actual denial raises step therapy, indication, or another plan-specific criterion before responding.
What prior failures does Premera Blue Cross typically require before approving Galcanezumab?
Premera Blue Cross's biologics step-therapy ladder for most indications begins with a conventional DMARD (methotrexate, sulfasalazine, leflunomide) or topical/inhaled first-line, then a step-1 biologic (typically a TNF inhibitor or adalimumab biosimilar), then the requested agent. Document trial duration (≥12 weeks for most biologics), dosing reached, and reason for discontinuation (inadequate response by disease-activity score, intolerance, or contraindication). For Galcanezumab, attach the specific disease-activity instrument Premera Blue Cross accepts (e.g., DAS28, PASI 75, HBI, Mayo) — appeals with raw symptom narrative but no scored instrument carry higher denial rates. Pharmacy-benefit handling is routed through Express Scripts. External-review escalation for Premera Blue Cross fully-insured policies sits with the WA insurance department.
How do I prep for a peer-to-peer with Premera Blue Cross on Galcanezumab (Emgality)?
Lead with the FDA-approved indication and the specific clinical criteria the policy lists. Have the patient's chart open, document number, and policy URL on screen. State your name and credentials, the policy number, the indication, and the documented failures of step-therapy alternatives. Keep notes — if the P2P reviewer overturns, get the decision in writing.
Related PA criteria
Generate the Galcanezumab (Emgality) PA packet
Open ApprovalHelp — generate a Galcanezumab (Emgality) prior-auth packet tailored to Premera Blue Cross's criteria, with prescriber attestation and step-therapy documentation pre-filled.
Get started →Contact: hello@approvalhelp.com